Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2021. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
4555462016 | Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
4555463014 | Abacavir (as abacavir sulfate) 300 mg and lamivudine 150 mg and zidovudine 300 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Plays role | Antiretroviral therapeutic role | false | Inferred relationship | Some | ||
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Zidovudine (substance) | true | Inferred relationship | Some | 3 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Abacavir (substance) | true | Inferred relationship | Some | 2 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Abacavir sulfate (substance) | true | Inferred relationship | Some | 2 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 3 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Lamivudine (substance) | true | Inferred relationship | Some | 1 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 2 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing only abacavir and lamivudine and zidovudine in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Lamivudine (substance) | true | Inferred relationship | Some | 1 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Zidovudine (substance) | true | Inferred relationship | Some | 3 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 3 | |
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets